ArriVent BioPharma, Inc. (AVBP) vs Cytek Biosciences, Inc. (CTKB)
A side-by-side comparison of ArriVent BioPharma, Inc. and Cytek Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$14.51HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
CTKB
Cytek Biosciences, Inc.
$5.58HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — AVBP vs CTKB
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)CTKB -25.9% (-9.5%/yr)AVBP compounded faster over this window
AVBP CTKB
AVBP vs CTKB: by the numbers
- •CTKB is the larger company ($720M vs $676M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -38.98% net margin).
Metrics side by side
Valuation
| Metric | AVBP | CTKB |
|---|---|---|
| P/S ratio | N/A | 3.48 |
| P/B ratio | 1.84 | 2.24 |
Profitability
| Metric | AVBP | CTKB |
|---|---|---|
| Gross margin | 0.00% | 53.23% |
| Operating margin | 0.00% | -21.60% |
| Net margin | 0.00% | -38.98% |
| ROE | -44.63% | -25.03% |
| ROIC | -47.96% | -12.00% |
Growth (annualized)
| Metric | AVBP | CTKB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 13.37% |
| Total return CAGR (5Y) | N/A | -23.16% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.